Get access

Phase 2 Trial of the Continuous IV Administration of Interferon-β in Patients With Disseminated Malignant Melanoma

Authors

  • Susanne Voelter-Mahlknecht MD,

    1. From the University of Mainz, Department of Occupational, Social and Environmental Medicine, Mainz, Germany;1 the University of Tübingen, Department of Dermatology, Tubingen, Germany,2 and the University of Heidelberg Medical Center, Department of Hematology/Oncology, Heidelberg, Germany3
    Search for more papers by this author
  • 1,2 Ulrich Mahlknecht MD, PhD,

    1. From the University of Mainz, Department of Occupational, Social and Environmental Medicine, Mainz, Germany;1 the University of Tübingen, Department of Dermatology, Tubingen, Germany,2 and the University of Heidelberg Medical Center, Department of Hematology/Oncology, Heidelberg, Germany3
    Search for more papers by this author
  • 3 Stephan Letzel MD, PhD,

    1. From the University of Mainz, Department of Occupational, Social and Environmental Medicine, Mainz, Germany;1 the University of Tübingen, Department of Dermatology, Tubingen, Germany,2 and the University of Heidelberg Medical Center, Department of Hematology/Oncology, Heidelberg, Germany3
    Search for more papers by this author
  • and 1 Gerhard Fierlbeck MD, PhD 2

    1. From the University of Mainz, Department of Occupational, Social and Environmental Medicine, Mainz, Germany;1 the University of Tübingen, Department of Dermatology, Tubingen, Germany,2 and the University of Heidelberg Medical Center, Department of Hematology/Oncology, Heidelberg, Germany3
    Search for more papers by this author

Susanne Voelter-Mahlknecht, MD, University of Mainz, Department of Occupational, Social and Environmental Medicine, Obere Zahlbacher Strasse 67, D-55131 Mainz, Germany
E-mail: voelterm@uni-mainz.de

Abstract

Background: Interferons have been reported to significantly contribute to tumor suppression via both induction of p53 gene expression and inhibition of angiogenesis.

Objective: The assessment of treatment toxicity and antitumoral effectiveness of continuous IV administration of interferon-β based on an overall evaluation of laboratory, radiographic, and clinical parameters observed during the trial.

Methods: The authors treated patients with advanced malignant melanoma with continuous IV infusions of 1 × 106 IU interferon-β daily (approx0.6 × 106 IU interferon-β/m2 daily). Results: Continuous IV administration of interferon-β had no significant effect on overall patient outcome. Interferon side effects were not a reason for treatment discontinuation in any of the patients observed during this trial.

Conclusions: Continuous IV interferon-β had no significant effect on overall patient outcome in a group of patients with advanced malignant melanoma. To our knowledge, this is the first report on the continuous IV administration of interferon-β in patients with advanced malignant melanoma.

Ancillary